Hers Prescription Process: How the Intake Works, What Gets Prescribed, and Whether It's Worth It

How the Hers Intake Process Works

The intake begins with a condition-specific questionnaire covering medical history, current medications, allergies, and symptom severity. Hers routes completed questionnaires to a licensed provider (physician, NP, or PA) in the patient's state. Most prescriptions are issued within 24 hours without a synchronous visit.

This asynchronous model mirrors what the American Telemedicine Association describes as "store-and-forward" care, where clinical information is collected and reviewed at a later time rather than during a live encounter [1]. The ATA's 2024 practice guidelines note that asynchronous models are appropriate for low-acuity conditions but recommend synchronous evaluation for complex medication management [1]. Hers does offer optional video consultations, though the platform's default path skips them for straightforward cases like topical treatments or oral contraceptives.

The questionnaire screens for contraindications specific to each medication category. For spironolactone (used in their hair and skin lines), the intake asks about potassium levels, kidney function, and concurrent ACE inhibitor use. For GLP-1 agonists, it screens for personal or family history of medullary thyroid carcinoma and pancreatitis. The depth of screening varies by product risk profile, which is clinically appropriate.

What Medications Does Hers Actually Prescribe?

Hers dispenses FDA-approved drugs across six primary categories: finasteride and minoxidil for hair loss, tretinoin and spironolactone for skin, SSRIs and buspirone for anxiety and depression, sildenafil for sexual wellness, semaglutide and liraglutide for weight management, and bioidentical hormones for perimenopause and menopause.

The hair loss category is their most established line. Topical minoxidil 2% is FDA-approved for female pattern hair loss based on data showing 13% mean increase in non-vellus hair count at 32 weeks versus placebo [2]. Oral minoxidil at low doses (0.25-2.5 mg) is prescribed off-label, supported by a 2022 systematic review in the Journal of the American Academy of Dermatology covering 17 studies and 634 patients that found mean hair density increases of 15-25% [3].

For their mental health line, Hers prescribes generic SSRIs (sertraline, fluoxetine, escitalopram) and buspirone. The STARD trial (N=4,041) demonstrated that approximately 33% of patients with major depressive disorder achieve remission on their first SSRI trial, with cumulative remission reaching 67% after four sequential treatment steps [4]. This is relevant because Hers' asynchronous follow-up model may limit the iterative dose optimization that STARD showed is often necessary.

Their weight management category now includes compounded semaglutide, entering a market where the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo [5]. The FDA has raised concerns about compounded GLP-1 products specifically, issuing a 2024 safety communication noting reports of adverse events linked to compounded semaglutide preparations that may differ in purity and potency from the branded product [6].

Is Hers Legitimate? Evaluating Clinical Standards

Hers operates through licensed providers and dispenses FDA-approved medications through licensed pharmacies. That baseline makes it a legitimate medical service. The more useful question is whether their care model meets evidence-based standards for each condition they treat.

For low-complexity prescriptions (topical minoxidil, tretinoin, oral contraceptives), the asynchronous model is clinically defensible. The American Academy of Dermatology's 2020 position statement on teledermatology supports asynchronous evaluation for conditions where visual assessment and structured history are sufficient for diagnosis [7].

For higher-complexity prescriptions (SSRIs, GLP-1 agonists, HRT), the standard of care typically involves more intensive monitoring. The American Psychiatric Association recommends follow-up within 1-2 weeks of initiating or adjusting antidepressant therapy [8]. Hers offers provider messaging but does not enforce structured follow-up intervals for mental health prescriptions. This gap is not unique to Hers. Most D2C telehealth platforms share this limitation.

The Endocrine Society's 2022 guidelines for menopausal hormone therapy recommend baseline mammography, assessment of cardiovascular risk factors, and periodic reassessment of symptoms and risks [9]. Hers' HRT intake does collect cardiovascular history and mammography status, but the absence of mandatory periodic reassessment visits is a structural weakness relative to traditional endocrinology practice.

Hers vs. Alternatives: How the Platform Compares

Direct competitors include Nurx, Wisp, and Alloy (for HRT specifically). Traditional telehealth platforms like Teladoc and MDLive offer broader medical services but lack the D2C subscription convenience. The comparison depends on what you're seeking treatment for.

For hair loss, Hers' bundled topical formulations (minoxidil + spironolactone + tretinoin compounds) offer convenience over purchasing generics separately, though at a price premium. A month of OTC minoxidil 2% costs $15-25 at retail pharmacies. Hers charges $30-85/month for their hair loss subscriptions depending on formulation.

For HRT, Alloy Health focuses exclusively on menopause and offers standardized lab protocols with their prescriptions. The Women's Health Initiative (N=27,347) established that HRT decisions require individualized risk-benefit analysis considering age, time since menopause, and cardiovascular risk factors [10]. Platforms that enforce lab monitoring and periodic reassessment are better positioned to deliver this individualized approach.

For weight management with GLP-1s, Hers competes with Calibrate, Found, and Ro. The differentiator is whether the platform requires metabolic labs (fasting glucose, HbA1c, lipid panel) before and during treatment. Hers does require baseline labs for their GLP-1 program. According to the Obesity Medicine Association's 2024 clinical practice statement, patients on GLP-1 receptor agonists should have renal function and lipase monitored periodically, particularly during dose escalation [11].

The Subscription Model: Cost Structure and What You're Paying For

Hers operates on monthly auto-renewal subscriptions. Pricing varies by category: hair loss products range from $30-85/month, mental health medications from $25-85/month, and GLP-1 weight management from $199-399/month. These prices include the medication, provider access, and shipping.

The cost comparison against traditional care requires accounting for visit copays, pharmacy costs, and time. A 2023 analysis in Telemedicine and e-Health found that D2C telehealth platforms reduced total episode cost by 36% compared to in-person visits for dermatologic conditions, primarily through elimination of office visit fees and reduced time burden [12]. That math holds for simple prescriptions.

For complex conditions requiring lab monitoring, the cost advantage narrows or reverses. A patient on Hers' GLP-1 program at $299/month pays $3,588 annually. The same patient with commercial insurance might pay $25-50/month for branded Wegovy after meeting their deductible, plus periodic office visits. The uninsured patient faces a different calculus: Wegovy's list price of $1,349/month makes Hers' compounded alternative financially attractive despite clinical concerns about compounding quality.

No refunds are issued once medication ships. This is standard for dispensed prescriptions under pharmacy regulations, but patients should understand the commitment before subscribing.

Provider Quality and Oversight Structure

Hers contracts with a network of physicians, nurse practitioners, and physician assistants licensed in the patient's state. Providers are credentialed through a process the company describes as verifying board certification, active licensure, and malpractice history. Independent verification of their credentialing rigor is not publicly auditable.

The National Committee for Quality Assurance (NCQA) has not certified Hers' telehealth operations, though NCQA certification is voluntary and many legitimate telehealth companies operate without it. The Federation of State Medical Boards' 2023 report on telehealth noted that asynchronous prescribing raises specific quality concerns around diagnostic accuracy and continuity of care, recommending that platforms implement structured follow-up protocols [13].

One structural consideration: Hers' providers are reviewing intake questionnaires for a single platform's product formulary. This creates alignment between provider recommendations and available products. A provider reviewing a hair loss questionnaire on Hers can prescribe minoxidil, spironolactone, or finasteride from Hers' pharmacy. They cannot recommend a dermatology referral for biopsy if the pattern suggests scarring alopecia. The intake does include a question about whether you've been evaluated in person, which helps triage, but the financial model creates no incentive for referral-out.

Safety Monitoring and Medication Interactions

Drug interaction screening happens at intake through the medical history questionnaire. Patients list current medications, and the prescribing provider reviews for contraindications. This is standard practice. The limitation is that interaction screening at enrollment does not capture medications added later by other providers.

For spironolactone specifically, the drug carries risks of hyperkalemia that the FDA label recommends monitoring with periodic serum potassium checks [14]. Hers does not mandate follow-up labs for spironolactone prescriptions at their standard hair loss doses (25-100 mg). A 2019 retrospective study in JAMA Dermatology (N=974) found that hyperkalemia rates in young healthy women on spironolactone 25-200 mg for acne or hair loss were 0.72%, leading the authors to suggest that routine monitoring may be unnecessary in low-risk populations [15]. This provides clinical support for Hers' approach in otherwise healthy patients, though it does not eliminate the need for monitoring in patients with renal impairment or concurrent potassium-sparing medications.

For their HRT category, the North American Menopause Society's 2022 position statement recommends that hormone therapy be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals, with periodic reassessment [16]. Hers' subscription model, which auto-renews without mandatory check-ins, potentially works against this principle of periodic reassessment and dose minimization.

What the User Reviews Actually Show

Aggregated review data from Trustpilot and the BBB shows Hers holding approximately 4.0-4.2 out of 5 stars across platforms, with common positive themes being convenience, speed of prescription, and packaging discretion. Negative reviews cluster around three areas: difficulty canceling subscriptions, charges occurring before patients can evaluate whether the medication works, and limited provider interaction.

The subscription cancellation complaints mirror a broader D2C telehealth pattern. The FTC's 2024 "click-to-cancel" rule requires that canceling a subscription be as easy as signing up [17]. Reviews suggest Hers has improved cancellation accessibility since the rule took effect, though some patients still report friction.

Clinical outcome satisfaction is harder to assess from reviews. Hair regrowth expectations are frequently misaligned with biological timelines. Minoxidil requires 4-6 months of consistent use before visible results [2], but negative reviews often appear at the 1-2 month mark. This is a patient education gap, not a platform quality issue.

Who Should and Shouldn't Use Hers

The platform works well for patients seeking FDA-approved treatments for straightforward conditions: androgenetic alopecia, mild-moderate acne, uncomplicated anxiety, or basic sexual wellness prescriptions. These conditions have clear diagnostic criteria assessable via questionnaire and standard first-line treatments with well-characterized safety profiles.

Patients with complex medical histories, multiple comorbidities, or conditions requiring physical examination should pursue in-person or synchronous telehealth care. The American College of Obstetricians and Gynecologists recommends that HRT initiation include discussion of individualized risks based on personal and family history of breast cancer, cardiovascular disease, and venous thromboembolism [18]. While Hers' intake collects this information, the asynchronous format may not allow for the nuanced shared decision-making that complex HRT decisions warrant.

Patients currently on multiple medications managed by other providers should ensure their Hers provider has a complete medication list. The platform does not integrate with external electronic health records, meaning medication reconciliation depends entirely on patient self-report.